title: Augmented trial designs for evaluation of principal surrogates.
abstract: Observation of counterfactual intermediate responses, and evaluation of them as candidate surrogates, is complicated in a standard randomized trial as half of the responses are systematically missing by design. Although some augmentation procedures exist for obtaining counterfactual responses, they are specific to vaccine trials. We outline extensions to the existing augmentations and suggest augmentations of three trial designs outside the setting of vaccines. We outline the assumptions needed to identify the causal estimands of interest under each augmented design, under which standard likelihood-based methods can be used to evaluate intermediate responses as principal surrogates. Two of these designs, crossover and individual stepped-wedge, allow for the observation of clinical endpoints under both treatment and control for some subset of subjects and can therefore improve efficiency over standard parallel trial designs. The third, the treatment run-in design, allows for the observation of a baseline measure that may be as useful a surrogate as the true counterfactual intermediate response. As the evaluation methods rely on several assumptions, we also outline a remediation analysis, which can be used to help overcome assumption violations. We illustrate our suggested methods in an example from a drug-resistant tuberculosis treatment trial.
authors.affiliation: Biostatistics Research Branch NIAID NIH, Bethesda, MD, USA erin.gabriel@nih.gov.
authors.forename: Erin E
authors.initials: EE
authors.lastname: Gabriel
authors.affiliation: Biostatistics Research Branch NIAID NIH, Bethesda, MD, USA.
authors.forename: Dean
authors.initials: D
authors.lastname: Follmann
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D018592:Cross-Over Studies; D006801:Humans; D000069349:Linezolid / Q000494:pharmacology; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data*; D012107:Research Design / Q000706:statistics & numerical data*; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D000069349:Linezolid
keywords: Augmented trial design; Causal inference; Counterfactual responses; Principal surrogates
references.citation: Stat Med. 2015 Feb 10;34(3):381-95
references.pmid: 25352131
references.citation: Biometrics. 2002 Mar;58(1):21-9
references.pmid: 11890317
references.citation: Biometrics. 2013 Sep;69(3):561-9
references.pmid: 24073861
references.citation: J Infect Dis. 2007 Nov 1;196(9):1304-12
references.pmid: 17922394
references.citation: Biostatistics. 2015 Apr;16(2):400-12
references.pmid: 25236906
references.citation: Biostatistics. 2014 Apr;15(2):251-65
references.pmid: 24337534
references.citation: Biostatistics. 2014 Apr;15(2):266-83
references.pmid: 24285772
references.citation: Biometrics. 2010 Dec;66(4):1153-61
references.pmid: 20105158
references.citation: Biometrics. 2011 Dec;67(4):1442-51
references.pmid: 21517791
references.citation: EBioMedicine. 2015 Oct 09;2(11):1627-33
references.pmid: 26870788
references.citation: J Infect Dis. 2014 Nov 15;210(10):1573-81
references.pmid: 24823623
references.citation: N Engl J Med. 2012 Oct 18;367(16):1508-18
references.pmid: 23075177
references.citation: Biometrics. 2010 Jun;66(2):523-31
references.pmid: 19673864
references.citation: Biometrics. 2013 Jun;69(2):301-9
references.pmid: 23409839
references.citation: Biometrics. 2006 Dec;62(4):1161-9
references.pmid: 17156291
references.citation: Stat Med. 2008 Oct 15;27(23):4758-78
references.pmid: 17979212
references.citation: Biometrics. 2008 Dec;64(4):1146-54
references.pmid: 18363776
references.citation: Stat Med. 2011 Aug 30;30(19):2422-34
references.pmid: 21590703